Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406385 | 0.92 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL1406327 | 0.92 | ERBB2 (0.85) | ERBB2EGFR | |
| SCHEMBL1406784 | 0.92 | ERBB2 (0.85) | ERBB2EGFR | |
| SCHEMBL1406582 | 0.92 | ERBB2 (0.85) | ERBB2EGFR | |
| SCHEMBL1406648 | 0.91 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL1406435 | 0.91 | ERBB2 (0.84) | ERBB2EGFR | |
| SCHEMBL1406292 | 0.87 | ERBB2 (0.78) | ERBB2EGFR | |
| SCHEMBL1406311 | 0.87 | ERBB2 (0.77) | ERBB2EGFR | |
| SCHEMBL1406823 | 0.86 | ERBB2 (0.76) | ERBB2EGFR | |
| SCHEMBL1406226 | 0.86 | ERBB2 (0.74) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947676-B2 | 2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy-}ethanol; erbB2 receptor tyrosine kinase inhibitor; anticarcinogenic, antitumor agnet; solid tumor and nonsolid such as leukaemia, multiple myeloma and lymphoma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | claimed |
| EP-1838712-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| EP-1838712-B8 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| US-7947676-B2 | 2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy-}ethanol; erbB2 receptor tyrosine kinase inhibitor; anticarcinogenic, antitumor agnet; solid tumor and nonsolid such as leukaemia, multiple myeloma and lymphoma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| EP-1838712-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.